Russian billionaire may construct largest pharma plant in Belarus

9 March 2011

Vladimir Bryntsalov, one of Russia’s richest businessman, and the Belarusian Belbiopharm state concern, may invest up to $120 million in the construction of the largest pharmaceutical plant in Belarus. The new plant is expected to be built in 2015 on the base of a state pharmaceutical company Dialek.

Expected total production capacities of the plant were not disclosed. According to some Belarus media reports, however, the new facility will focus on the production of certain pharmaceutical drugs and antibiotics, which should replace their more expensive imported analogues.

Imports now account for 80% of market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK